LABA/LAMA fixed-dose combinations versus LAMA monotherapy in the prevention of COPD exacerbations: a systematic review and meta-analysis

BACKGROUND: Long-acting muscarinic antagonist (LAMA) monotherapy is recommended for chronic obstructive pulmonary disease (COPD) patients with high risk of exacerbations. It is unclear whether long-acting β2-agonist (LABA)/LAMA fixed-dose combinations (FDCs) are more effective than LAMAs alone in pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Ching-Yi, Chen, Wang-Chun, Huang, Chi-Hsien, Hsiang, Yi-Ping, Sheu, Chau-Chyun, Chen, Yung-Che, Lin, Meng-Chih, Chu, Kuo-An, Lee, Cheng-Hung, Wei, Yu-Feng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Systematic Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7350046/
https://www.ncbi.nlm.nih.gov/pubmed/32643547
http://dx.doi.org/10.1177/1753466620937194

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7350046/
https://www.ncbi.nlm.nih.gov/pubmed/32643547
http://dx.doi.org/10.1177/1753466620937194

Ejemplares similares